Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease

Recently, we confirmed the presence of enhanced neural reconstruction in Parkinson's disease and in an animal model of Parkinson's disease based on increased polysialic acid-like immunoreactivity. Changes in neurogenesis often appear parallel to changes in angiogenesis. Moreover, both these processes share similar modulating factors, like vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1). Using immunohistochemistry, we identified in this study upregulation of VEGF in the substantia nigra but not in the striatum of patients with Parkinson's disease by enzyme-linked immunosorbent assay. Such overexpression may participate in vascular remodeling and neurogenesis in the substantia nigra of Parkinson's disease.

[1]  H. Okano,et al.  Possibility for neurogenesis in substantia nigra of parkinsonian brain , 2005 .

[2]  E. Hirsch,et al.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian , 2005, Journal of Neural Transmission.

[3]  M. Miura,et al.  Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1β, and Expression of Caspase-11 in Mice* , 2004, Journal of Biological Chemistry.

[4]  Francis J. Martin,et al.  VEGF-mediated inflammation precedes angiogenesis in adult brain , 2004, Experimental Neurology.

[5]  T. Yasuhara,et al.  Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease , 2004, The European journal of neuroscience.

[6]  J. Rosenstein,et al.  Neurotrophic Effects of Vascular Endothelial Growth Factor on Organotypic Cortical Explants and Primary Cortical Neurons , 2003, The Journal of Neuroscience.

[7]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[8]  K. Jin,et al.  Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Palmer,et al.  Vascular niche for adult hippocampal neurogenesis , 2000, The Journal of comparative neurology.

[10]  J. Rosenstein,et al.  Transient Coexpression of Nestin, GFAP, and Vascular Endothelial Growth Factor in Mature Reactive Astroglia Following Neural Grafting or Brain Wounds , 1999, Experimental Neurology.

[11]  W. Silverman,et al.  Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures , 1999, Neuroscience.

[12]  E. Hirsch,et al.  Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.

[13]  J. LaManna,et al.  Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. , 1998, Brain research. Molecular brain research.

[14]  M. Fukui,et al.  VEGF and flt. Expression time kinetics in rat brain infarct. , 1996, Stroke.

[15]  Y Agid,et al.  Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.